Indonesia Anti-Rheumatic Drug Market Analysis Report 2022: A $4.35 Billion Market by 2027 Featuring Pfizer, GlaxoSmithKline, & F. Hoffmann-La Roche – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Indonesia Anti-Rheumatic Drug Market – Forecasts from 2022 to 2027” report has been added to ResearchAndMarkets.com’s offering.

Indonesia antirheumatic drugs market was valued at US$3,543.837 million in 2020. The market is projected to grow at a CAGR of 3.00% to attain a value of US$4,359.458 million by 2027.

The market for antirheumatic drugs in Indonesia is projected to witness a healthy CAGR throughout the forecast period, primarily on account of the high incidence of malaria throughout the country, along with the moderate prevalence of numerous rheumatic diseases, such as osteoarthritis and rheumatoid arthritis, among others.

Furthermore, the exponential growth of the geriatric population of the country is also bolstering the growing demand for numerous types of antirheumatic drugs throughout the country, thus positively impacting the market growth during the next five years. For instance, the population aged 65 and above in the country reached 15,677,491 by 2018 from 11,661,484 in 2008 (Source: The World Bank Group).

Furthermore, malaria is considered a serious health problem in the country. Socio-demographic factors are considered to be highly responsible for the high impact of malaria throughout the country. Also, according to the data from the World Health Organization, in 2017, the reported confirmed malaria cases in health facilities across the country were around 261,617.

Also, the division of the population based on high transmission (>1 case per 1000 population) was around 16.9 million, and low transmission (>1 case per 1000 population) was evaluated at around 247.1 million for the same period. Therefore, the high prevalence of malaria in Indonesia is also projected to be one of the key factors supplementing the antirheumatic drugs market growth in the country over the next five years.

Product Offerings by the market players in the Indonesian antirheumatic drugs market:

Bernofram pharmaceutical company, headquartered in Surabaya, Indonesia, develops effective and cost-efficient drugs for various diseases, including rheumatoid arthritis. Sulcolon, a brand name of Sulfasalzine. It is an anti-inflammatory drug. Sulfasalazine is used in the treatment of rheumatoid arthritis and inflammatory diseases associated with inflammatory bowel disease and ankylosing spondylitis. Usually, it is combined with other DMARDS if the patient is unresponsive to just one drug.

PT Kalbe Farma Tbk, is an Indonesian-based healthcare firm that develops OTC drugs, Prescription drugs, nutrition products, and energy drinks. Methotrexate Kable Injection, developed by the firm, is used in the treatment of rheumatoid arthritis, among many others. Methotrexate functions by inhibiting inflammation and reducing joint damage.

Key Topics Covered:

1. Introduction

1.1. Market Overview

1.2. COVID-19 Impact

1.3. Market Definition

1.4. Market Segmentation

2. Research Methodology

2.1. Research Data

2.2. Assumptions

3. Executive Summary

3.1. Research Highlights

4. Market Dynamics

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.4. Industry Value Chain Analysis

5. Indonesia Antirheumatic Drug Market Analysis, By Type of Disease

5.1. Introduction

5.2. Osteoarthritis

5.3. Rheumatoid Arthritis

5.4. Gout

5.5. Lupus

5.6. Others

6. Indonesia Antirheumatic Drug Market Analysis, By Type of Molecule

6.1. Introduction

6.2. Pharmaceuticals

6.3. Biopharmaceuticals

7. Indonesia Antirheumatic Drug Market Analysis, By Sales Channel

7.1. Introduction

7.2. Prescription

7.3. Over-The-Counter (OTC)

8. Competitive Environment and Analysis

8.1. Major Players and Strategy Analysis

8.2. Emerging Players and Market Lucrativeness

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Vendor Competitiveness Matrix

9. Company Profiles

9.1. Pfizer Inc.

9.2. GlaxoSmithKline plc

9.3. F. Hoffmann-La Roche Ltd

For more information about this report visit https://www.researchandmarkets.com/r/h0qenl

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900